Three compounds, one conversation

The GLP-1 conversation has exploded globally over the last two years. Semaglutide, sold as Ozempic and Wegovy, put the entire category on the map. Tirzepatide followed with stronger data. Now Retatrutide is generating serious clinical interest with results that outperform both.

For researchers in Bangkok, all three compounds are accessible locally with same-day delivery — something that simply doesn’t exist in most cities. But understanding the differences between them is essential before designing any research protocol. This guide breaks down exactly how they differ, what the data shows, and which compound suits which research focus.

What makes these compounds different at the receptor level

All three work on the GLP-1 (glucagon-like peptide-1) receptor, which regulates appetite, gastric emptying, and insulin secretion. The key difference is how many additional receptors each compound targets.

The progression is straightforward: each compound adds another receptor target, and each additional target amplifies the metabolic effect. More receptor pathways means more mechanisms working simultaneously.

What the clinical trials actually showed

Semaglutide showed approximately 15% body weight reduction in the STEP trials over 68 weeks at the 2.4mg weekly dose. This was a landmark result that drove enormous adoption of the branded product worldwide.

Tirzepatide outperformed semaglutide in head-to-head research. The SURMOUNT-1 trial showed up to 22.5% body weight reduction at the 15mg dose over 72 weeks, making it significantly more effective than semaglutide for metabolic research outcomes.

เรทแทรทรูไทด์ produced the most striking Phase 2 data of any compound in this class. At the 12mg dose over 48 weeks, researchers observed up to 24.2% body weight reduction — the highest figure ever recorded for a non-surgical weight intervention in a Phase 2 trial. Phase 3 data is currently being collected.

Direct comparison

How to choose between the three compounds

Semaglutide has the longest research history and the most published human data. For researchers who want the most studied compound in this class, it remains the benchmark. Bangkok Peptide Center does not currently stock semaglutide but we can source it on request — message us on WhatsApp.

Tirzepatide is the established step up from semaglutide. Head-to-head data shows it outperforms semaglutide consistently, and it has full FDA approval with a substantial body of Phase 3 data. For researchers wanting a well-documented dual agonist, Tirzepatide is the logical choice. Available now at Bangkok Peptide Center with same-day delivery.

เรทแทรทรูไทด์ represents the cutting edge of this research area. Its Phase 2 data is the strongest ever recorded in this compound class and it is the only triple agonist currently in late-stage clinical development. For researchers interested in the most potent metabolic peptide currently under study, Retatrutide is the compound to watch. Available now at Bangkok Peptide Center with same-day delivery.